Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 3 of 3 entries
Sorted by: Best Match Show Resources per page
Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial.

Clinical rheumatology

Durez P, Pavelka K, Lazaro MA, Garcia-Kutzbach A, Moots RJ, Amital H, Govoni M, Vastesaeger N.
PMID: 29752584
Clin Rheumatol. 2018 Jul;37(7):2017-2018. doi: 10.1007/s10067-018-4131-1.

The original publication contains two areas which require correcting. None of these errors change the results or conclusions of the article, but the authors wish to highlight the areas of change to the reader.

Effectiveness and safety of infliximab in two cases of severe chondrocalcinosis: nine years of follow-up.

Case reports in rheumatology

Bruges-Armas J, Bettencourt BF, Couto AR, Lima M, Rodrigues AM, Vastesaeger N, Brown MA.
PMID: 25436167
Case Rep Rheumatol. 2014;2014:536856. doi: 10.1155/2014/536856. Epub 2014 Nov 11.

Objectives. To investigate the efficacy of infliximab in the treatment of severe calcium pyrophosphate deposition diseases (CPPD). Methods. Two patients with severe CPPD and diffuse idiopathic skeletal hyperostosis- (DISH-) like phenotype are described. Both patients were resistant to therapy...

[Coronarographic aspects of coronary occlusions].

Acta cardiologica

GHYS A, VASTESAEGER MM.
PMID: 13827781
Acta Cardiol. 1960;15:120-8.

No abstract available.

Showing 1 to 3 of 3 entries